Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR5A2 | O00482 | 1/20 | 1.00 |
| ▸ | NR5A1 | Q13285 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.88 |
| ▸ | FABP3 | P05413 | 1/20 | 0.78 |
| ▸ | RECQL | P46063 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.66 |
| ▸ | PTAFR | P25105 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.63 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimyristoylphosphatidylcholine SCHEMBL244839 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL10498112 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Dimyristoylphosphatidylcholine SCHEMBL37475 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL234790 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL233046 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL22693933 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL231824 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL2036043 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| SCHEMBL24563 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 | |
| Colfosceril Palmitate SCHEMBL2734250 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR5A2NR5A1MAPTFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038304-A | Chikungunya virus intrusion model, establishing method and application | 中国中医科学院中医基础理论研究所 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026099382-A1 | MEANS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE EFFECTOR CELLS | NANOCELL THERAPEUTICS HOLDINGS B.V. (NL) | 2026-05-15 | — | — | WO | disclosed |
| US-12569437-B2 | Disease-site-specific liposomal formulation | OSAKA UNIVERSITY (JP) | 2026-03-10 | — | — | US | disclosed |
| US-12569449-B1 | Cationic lipid compound, and preparation method therefor and use thereof | RONGCAN (SHANGHAI) BIOTECH CO., LTD (CN) | 2026-03-10 | — | — | US | disclosed |
| EP-4624451-A1 | CARBAMATE-BOND-CONTAINING LIPID COMPOUNDS AND USE THEREOF | Rongcan (Shanghai) Biotech CO., Ltd (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250268839-A1 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-08-28 | — | — | US | disclosed |
| US-20250213665-A1 | METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-07-03 | — | — | US | disclosed |
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-06-26 | — | — | US | disclosed |
| US-12319644-B2 | Lipid compound containing carbamate bond and applications thereof | RONGCAN (SHANGHAI) BIOTECH CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| US-20250154167-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | KaNDy Therapeutics Limited (GB) | 2025-05-15 | — | — | US | disclosed |
| WO-2006079014-A2 | TOPICAL ADMINISTRATION PERMITTING PROLONGED EXPOSURE OF TARGET CELLS TO THERAPEUTIC AND PROPHYLACTIC NUCLEIC ACIDS | INTROGEN THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060134801-A1 | Methods and compositions involving MDA-7 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-06-22 | — | — | US | disclosed |
| US-20060110405-A1 | Plasma or serum fraction for treatment and prevention of viral infections and related conditions | BUCKHEIT ROBERT W JR | 2006-05-25 | — | — | US | disclosed |
| CN-1759122-A | compositions and methods comprising MDA-7 | UNIV TEXAS (US) | 2006-04-12 | — | — | CN | disclosed |
| US-20060002995-A1 | Pharmaceutical porous particles | ADAGIT (SE) | 2006-01-05 | — | — | US | disclosed |
| EP-1603943-A2 | METHODS AND COMPOSITIONS INVOLVING MDA-7 | Board of Regents, The University of Texas System (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1569626-A1 | PHARMACEUTICAL POROUS PARTICLES | Adagit (SE) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004078124-A2 | METHODS AND COMPOSITIONS INVOLVING MDA-7 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004054556-A1 | PHARMACEUTICAL POROUS PARTICLES | ADAGIT (SE) | 2004-07-01 | — | — | WO | disclosed |
| US-20040009939-A1 | Methods of enhancing immune induction involving MDA-7 | BOARD OF REGENT, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205262-A1 | SPHINGOLIPID-LOADED NANOBIOLOGICS FOR IMMUNE REGULATION | APOB, APOL1, SGMS1 | SMN1; SMN2 962/4885NR5A2 2894/4885NR5A1 2980/4885 |
| US-12569437-B2 | Disease-site-specific liposomal formulation | PTGER1, PLA2R1, LPAR2 | SMN1; SMN2 1775/4885NR5A2 1124/4885NR5A1 2348/4885 |
| US-12319644-B2 | Lipid compound containing carbamate bond and applications thereof | NPC1L1, NPC1, LCAT | SMN1; SMN2 3431/4885NR5A2 2586/4885NR5A1 3874/4885 |
| US-12569449-B1 | Cationic lipid compound, and preparation method therefor and use thereof | CETP, SLC39A11, PCTP | SMN1; SMN2 965/4885NR5A2 1902/4885NR5A1 724/4885 |
| US-20250213665-A1 | METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS | CD47, MYD88, IL2 | SMN1; SMN2 1106/4885NR5A2 2541/4885NR5A1 2290/4885 |
| US-20250154167-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | CYP19A1, MTNR1B, SHBG | SMN1; SMN2 3478/4885NR5A2 51/4885NR5A1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.